TY - ELEC TI - Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma AU - josh@comocreative.com T2 - Arcellx AB - GAITHERSBURG, Md., April 6, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for ACLX-001, an engineered cell therapy for the treatment of multiple myeloma. ACLX-001 is the first clinical application of theRead More DA - 2021/04/06/T20:09:27+00:00 PY - 2021 LA - en-US UR - https://arcellx.com/arcellx-announces-fda-clearance-of-ind-application-for-aclx-001-a-controllable-cell-therapy-utilizing-the-companys-arc-sparx-platform-for-the-treatment-of-multiple-myeloma/ Y2 - 2021/04/13/16:45:13 ER -